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Summary: The urinary excretion of pyridinium cross-links was measured in 70 second morning urine samples
from 49 patients following renal transplantation.
One and three months after renal transplantation, the urinary excretion of pyridinium cross-links was higher
(p < 0.05) than at one week after transplantation. At all times after transplantation, the values for the excretion of
pyridinium cross-links were correlated with the bone alkaline phosphatase concentrations (p < 0.001). However,
there was no correlation between parathyrin concentrations and the values for the excretion of pyridinium cross-
links (p > 0.05). This rise in the excretion of pyridinium cross-links is probably due to an increase of bone resorp-
tion caused by cyclosporin A and/or glucocorticoids.
In the case of 17 urines with excretion values of pyridinium cross-links above the upper reference limit (pyridinoline
equivalents, 93 /mol creatinine), only 2 (12%) of the corresponding sera showed increased bone alkaline
phosphatase values. In patients following renal transplantation simultaneous assessment of bone formation and bone
resorption (determined from bone alkaline phosphatase serum concentrations and the excretion of pyridinium cross-
links) may therefore enhance the diagnostic sensitivity for detecting effects on bone metabolism.
Introduction index of the activity of bone resorption (e. g. due to pri-
rr, „™, ^ , . mary hyperparathyroidism) (3).Type I collagen accounts for about 90% of the organic
matrix of mineralized bone, the organic matrix is stabi- Bone alkaline phosphatase (EC 3.1.3.1) is localized in
lized by the formation of pyridinium cross-links between the plasma membrane of osteoblastic cells and may be
the terminal, non-helical part of a type I collagen mole- considered as a marker of osteoblastic activity and of
cule and the helical region of another. The cross-links bone formation (4).
found in type I collagen of bone are formed from two jn chronic renal failure secondary hyperparathyroidism
hydroxylysine residues and one lysine residue (= de- ensues from diminished calcitriol production and im-
oxypyridinoline) or from three hydroxylysine residues paired excretion of inorganic phosphate. This leads to
(= pyridinoline) (1). When the collagen matrix is de- different forms of osteopathy including osteitis fibrosa,
graded, both kinds of cross-links are released into the osteomalacia and suppressed bone remodeling,
circulation and excreted in the urine. Deoxypyridinoline Following renal transplantation, the restoration of glo-
is found almost exclusively in bone, whereas pyridino- merular filtration does not always completely normalize
line is located in the collagen fibrils of bone as well the structure and function of bone tissue (e. g. hyper-
as cartilage (for review see 1. c. (2)). The excretion of parathyroidism may persist due to the increased mass of
pyridinium cross-links in urine is considered to be an the parathyroid glands). Additionally, new skeletal de-
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rangements result from the action of the immunosup-
pressive agents that are used to maintain the allograft
(for review see 1. c. (5)).
The present report describes the use of a competitive
enzyme immunoassay for determination of the urinary
excretion of pyridinium cross-links in the follow-up of
patients receiving renal transplants. Excretion values for
pyridinium cross-links were compared with bone alka-
line phosphatase mass concentrations (as determined im-
munoradiometrically) as well as with intact parathyrm
concentrations in plasma.




We examined 90 venous blood specimens (serum as well as
plasma; in the latter case the potassium salt of ethylenediamme-
tetraacetic acid was used as anticoagulant) and 70 second morning
urine samples from 49 patients (26 males, 23 females; age-range
25-66 years) who had undergone cadaveric renal transplantation.
Samples were obtained between 8.00 and 10.00 a.m.
Cyclosporin A was given i. v. during the first 2 postoperative days
at a daily dose of 1 mg/kg body weight, thereafter in daily oral
doses of 5 mg/kg body weight. The dosage was adapted to achieve
a concentration of cyclosporin A in whole blood between 120 and
160 μg/l (for determination of cyclosporin A see below). Azathio-
prine was given at a daily oral dose of 2 mg/kg body weight. Meth-
ylprednisolone was given during the first 2 postoperative days at a
daily dose of 250 mg i. v., during the next 4 days at a daily oral
dose of 100 mg, followed thereafter by a daily oral dose of 1 mg/
kg body weight, gradually decreasing to 0.1 mg/kg body weight 2
months after transplantation.
Tables 1 and 2 give further information on the sampling times of
serum, plasma and urine.
shows 100% cross-reactivity with deoxypyridinolme. A calibration
curve was constructed by employing a 4-parameter curve fitting
equation. Between-assay imprecision was < 10% Urinary excre-
tion of pyridinium cross-links is given as pyndmolme equivalents
in μηιοΐ/mol creatinine.
The following reference interval (2.5th to 97.5th percenttle) for
excretion of pyridinium cross-links in second morning urine sam-
ples was established in apparently healthy persons (urine samples
were obtained between 8.00 and 10.00 a.m.): pyridinoline equiva-
lents 13-93 (median: 46) μιηοΐ/mol creatinine (n = 99; 51 males
and 48 females; range of age: 19-62 [median: 29] years). TTiere
was no dependence of reference values on sex (p > 0.1).
Determination of bone alkaline phosphatase mass
concentration in serum
Bone alkaline phosphatase mass concentration was determined by
an immunoradiornetric assay (Tandem®-R Ostase™; Hybntech
Inc., San Diego, CA [U. S. A.]; no. 3040 BE; lot No. 35 077 08G)
employing two antibodies against two different epitopes of the
bone alkaline phosphatase molecule. A calibration curve was con-
structed by linear interpolation between the plotted analytical re-
sults. Between-assay imprecision was < 10%.
The following reference intervals (2.5th-97.5th percentile) for
bone alkaline phosphatase mass concentration in serum were estab-
lished in apparently healthy persons:
(1) 3.8-21.3 μg/l (males, n = 51)
(2) 3.4-15.0 μg/l (females, n =? 51).
The age-ranges were 20-55 years (males) and 18-56 years (fe-
males).
Determination of intact parathyrin concentration in
plasma
Concentration of intact parathyrin was determined by employing
N-tact® PTH (INCSTAR Corporation, Stillwater, Minnesota
[U.S.A.]; No. 22800) (reference interval: 1.1-5.8 pmol/1).
Determination of urinary excretion of pyridinium
"cross-links"
Urinary excretion of pyridinium cross-links was determined by a
competitive enzyme immunoassay (Collagen Crosslinks™ Kit;
Metra Biosystems Inc.; Palo Alto, CA [U. S. A.]; No. 8001; lot No.
3F01) employing a polyclonal antibody against pyridinoline which
Determination of creatinine concentration in serum
and urine
The creatinine concentration in serum and urine was determined
with the fully mechanized analyser Hitachi/BM 704 (Boehringer
Mannheim GmbH, Mannheim, Germany), employing a kinetic
modification of the Jaffe procedure (7).
Tab. 1 Comparison of urinary excretion of pyridinium cross-links at different times after renal
transplantation.










• (n = 11)
Pyridinoline equivalents
[μηιοί Χ mol"1 creatinine]
54.7 ± 9.6 67.4 ± 13.1 83.7 ±26.1* 40.7 ± 9.0 45.9 ±5.1
Median ± SEM (standard error of arithmetic mean) is given.
Values obtained 1, 3, 6 and 12 months following transplantation were compared with those obtained
1 week after transplantation.
* p < 0.05
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Tab. 2 Comparison of bone alkaline phosphatase mass concentrations in serum and intact parathyrin






































Median ± SEM (standard error of arithmetic mean) is given.
Values obtained after transplantation were compared with those obtained before transplantation.
* p < 0.05
Determination of Ζ,-γ-glutamyl transferase activity
concentration in serum
Zxy-Glutamyl transferase activity concentration was determined ac-
cording to Szasz (8) using the fully mechanized analyser Hitachi/
BM 737 (Boehringer Mannheim GmbH, Mannheim, Germany)
(normal range: 6-28 U/l [males] and 4-18 U/l [females]).
Determination of cyclosporin A in whole blood
Cyclosporin A was determined in the supernate of deproteinized
whole blood (anticoagulant: potassium salt of ethylenediamine-
tetraacetic acid), employing the analyser TDx® (Abbott GmbH,
Wiesbaden, Germany) and a monoclonal antibody against cyclo-
sporin A.
Statistical methods
The statistical methods employed include the U-test according to
Wilcoxon, Mann & Whitney (two-tailed) for unpaired samples, lin-
ear regression equations, as well as linear correlation coefficients
(9).
Results
Cross-sectional study of biochemical
quantities before and after renal transplanta-
tion
One, 6 and 12 months after renal transplantation, urinary
excretion values of pyridinium cross-links did not sig-
nificantly differ from those obtained 1 week following
transplantation (p > 0.05). There was a rise of excretion
values 3 months (p < 0.001) after renal transplantation
compared with the values obtained 1. week following
transplantation.
Before transplantation the median of parathyrin concen-
trations was elevated, whereas that of bone alkaline
phosphatase values was within the reference limits.
Bone alkaline phosphatase levels decreased 1 week
following renal transplantation (p < 0.01) but rose again
1 month after renal transplantation (p < 0.05). The con-
centrations of parathyrin following renal transplantation
did not significantly differ from those before renal trans-
plantation (p > 0.05) (tab. 1 and 2).
Relat ionship between urinary excretion of
pyridinium cross-links and intact parathyrin
values after renal t ransplantat ion
Out of 49 sera whose corresponding plasma samples
showed increased parathyrin values (> 5.8 pmol/1), 13
(27%) displayed urinary excretion values of pyridinium
cross-links above the upper reference limit (pyridinoline
equivalents, 93 μιηοΐ/mol creatinine) (tab. 3 and fig. 1).
Relationship between urinary excretion of
pyridinium cross-links and bone alkaline
phosphatase concentrations after renal
transplantation
In the case of 17 urines with concentrations of pyridin-
ium cross-links above the upper reference limit (pyridi-
noline equivalents, 93 μιηοΐ/mol creatinine), only 2
(12%) of the corresponding sera showed increased bone
alkaline phosphatase values (>21.3 μg/l [males] and
> 15.0 μg/l [females]). In all serum samples with bone
alkaline phosphatase values exceeding the upper refer-
ence limit, the Ζ,-γ-glutamyl transferase activity concen-
trations were within the reference interval (tab. 4 and
fig. 2).
Tab. 3 Relationship between urinary excretion of pyridinium
cross-links and intact parathyrin concentrations in 70 plasma/urine
samples (from 49 patients) obtained after renal transplantation.
Number of plasma
samples with

















b pyridinoline equivalents, 93 μηιοΐ/mol creatinine
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Re la t ionsh ip between bone a l k a l i n e
phosphatase concentrations and intact
pa ra thy r in values after renal t ransp lan ta t ion
Out of 49 sera whose corresponding plasma samples
showed increased parathyrin values (> 5.8 pmol/1), 8
(18%) displayed bone alkaline phosphatase concentra-
tion above the upper reference limit (21.3 μg/l [males]
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Fig. 1 Relationship between urinary excretion of pyridinium
cross-links and intact parathyrin concentrations in 70 plasma/urine
samples from 49 patients following renal transplantation.
The horizontal line indicates the upper reference limit (97.5th per-
centile) of pyridinium cross-links excretion (pyridoline equivalents,
93 μΓηοΙ/mol creatinine). The vertical line denotes the upper refer-
ence limit (97.5th percentile) of parathyrin concentration (5.8
pmol/1).
Tab. 4 Relationship between urinary excretion of pyridinium
cross-links and bone alkaline phosphatase mass concentrations in
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Fig. 2 Comparison between urinary excretion of pyridinium
cross-links and bone alkaline phosphatase mass concentrations in
70 serum/urine samples from 49 patients following renal transplan-
tation. % .<?_
The horizontal and vertical lines indicate the upper reference limits
(97.5th percentile) of pyridinium cross-links excretion (pyridino-
line equivalents, 93 μιτιοΐ/πιοί creatinine) and bone alkaline phos-
phatase (17.7 μg/l) without taking into consideration the depen-







21.3 ug/1 [males] and 15.0 μδ/1 [females], respectively
pyridinoline equivalents, 93 μΐΏοΙ/ηηοΙ creatinine
Ο 10 20 30 40 50 60
Intact parathyrin concentration [pmol/l]
Fig. 3 Relationship between bone alkaline phosphatase mass con-
centrations and intact parathyrin values in 70 serum/plasma sanv
pies from 49 patients following renal transplantation.
The horizontal line indicates the upper reference limit (97.5th per-
centile) of bone alkaline phosphatase (17.7 μg/l) without taking
into consideration the dependence of bone alkaline phosphatase
reference values on sex. The vertical line denotes the upper refer-
ence limit (97.5th percentile) of parathyrin concentration (5:8
pmol/1). » ;
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Before 1 week 1 month 3 months
after renal transplantation
Fig. 4 Follow-up of bone alkaline phosphatase concentrations
(fig. 4a) and pyridinium cross-links excretion values (fig. 4b) in
12 patients showing bone alkaline phosphatase concentrations
within or below the reference interval before renal transplantation.
The shaded areas denote the reference limits of bone alkaline phos-
1 week 1 month
after renal transplantation
3 months
phatase concentrations (3.6-17.7 μg/l) and of pyridinium cross-
links excretion (13—93 μιηοΐ/mol creatinine) without taking into
consideration the dependence of bone alkaline phosphatase values
upon sex.
Follow-up of the excretion of pyridinium
cross-links and the concentration of bone al-
kaline phosphatase after renal transplantation
The plasma concentration of bone alkaline phosphatase
and the urinary excretion of pyridinium cross-links were
monitored in 12 patients who showed a bone alkaline
phosphatase concentration within (10 cases) or below
the reference interval (2 cases).
There was a decrease of bone alkaline phosphatase 1
week after renal transplantation (p < 0.01) compared
with the corresponding concentrations before transplan-
tation. Bone alkaline phosphatase concentrations
increased again 1 month following transplantation
(p < 0.05). Three months after transplantation, bone al-
kaline phosphatase mass concentrations were higher
than before transplantation (p < 0.05). There was a rise
in the urinary excretion of pyridinium cross-links 1 and
3 months after transplantation, compared with the corre-
sponding values 1 week following transplantation
(p < O. 5). Excretion levels of cross-links and mass
concentrations of bone alkaline phosphatase were corre-
lated at all times following transplantation (p < 0.001)
(tab. 5 and fig. 4).
Discussion
Persistence of high intact parathyrin concentrations
r M · ι , . . / ,following renal transplantation is due to a hypersecre-
tion of this hormone by hyperplastic parathyroid glands
(10).
A follow-up revealed a rise of bone alkaline phosphatase
concentrations 3 months after renal transplantation. In
view of the lack of correlation between intact parathyrin
and bone alkaline phosphatase concentrations, it seems
unlikely that parathyrin action on bone tissue is respon-
sible for this increase.
Several groups have observed an increase of bone alka-
line phosphatase following renal transplantation (II , 12)
which is most probably due to an activation of osteo-
blasts by cyclosporin A (13):
Tab. 5 Correlation coefficients between urinary excretion of pyri-
dinium cross-links, concentrations of bone alkaline phosphatase,
intact parathyrin values and serum creatinine levels in 28 serum/
plasma/urine samples from 12 patients after renal transplantation.
Analytes
Pyridinium cross-links
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(a) thirteen of 17 patients with normal alkaline phosplia-
tase activities before renal transplantation who were
treated with cyclosporin A showed increased alkaline
phosphatase values one year after renal transplantation
compared with only 1 of 12 patients receiving azathio-
prine/prednisolone (14);
(b) reduction of the cyclosporin A dosage results in re-
duced bone alkaline phqsphatase values (4);
(c) histomoiphometric data show that osteoblast activity
is increased in patients following renal transplantation
who have received cyclosporin A as an immunosuppres-
sive agent (14);
(d) in rats cyclosporin A produced high bone remod-
elling, with bone resorption exceeding bone formation,
when daily cyclosporin A oral doses of 15 mg/kg body
weight were administered (15).
The urinary excretion of pyridinium cross-links was
increased 1 and 3 months after renal transplantation.
This may be due either to high bone remodelling in-
duced by cyclosporin A (15) or to an enhancement of
bone resorption caused by glucocorticoids (16).
Glucocorticoids cause bone loss by diminishing the con-
version of precursor cells to functioning osteoblasts and
by decreasing the synthesis of collagen (5). A decrease
of bone alkaline phosphatase values within the first
week following renal transplantation can be explained
by the high doses of corticosteroids given in this
period (17).
There was a correlation between the serum mass con-
centrations of bone alkaline phosphatase and the urinary
concentrations of pyridinium cross-links following renal
transplantation. This is in concordance with findings in
patients with primary hyperparathyroidism (3) or bone
metastases (18), in which osteobla'stic and osteoclastic
activity are usually coupled.
For the interpretation of bone alkaline phosphatase val-
ues (as determined immunoradiometrically) it has to be
taken into account that the antibodies employed in the
test show 16% cross reactivity with liver alkaline phos-
phatase (19, 20). In the sera examined in the present
study interference by liver alkaline phosphatase can be
excluded since all sera with increased bone alkaline
phosphatase mass concentrations showed Ζ,-γ-glutamyl
transferase activity concentrations within the reference
range.
It is worth mentioning that only 2 (12%) out of 17 urines
with excretion values of pyridinium cross-links above
the upper reference limit were characterized by
increased bone alkaline phosphatase values. In patients
following renal transplantation simultaneous assessment
of bone formation and bone resorption (determined frofrr
bone alkaline phosphatase serum concentrations and the
excretion of pyridinium cross-links) may therefore en-
hance the diagnostic sensitivity for detecting effects on
bone metabolism.
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